SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
SafeHeal has raised $39.9M in total funding. The most recent round was Series C. The last funding was announced in April 2025.
SafeHeal's investors include Sofinnova Partners, Genesis Medtech, Gideon Strategic Partners, M&L Healthcare Investments, MedTech Innovator.
SafeHeal is headquartered in Paris, France.
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
SafeHeal is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SafeHeal — Funding & Investors." VCBacked, April 29, 2025, https://www.vcbacked.co/company/safeheal. Accessed October 25, 2026.
VCBacked. (2025). SafeHeal — Funding & Investors. Retrieved October 25, 2026, from https://www.vcbacked.co/company/safeheal
{{cite web |title=SafeHeal — Funding & Investors |url=https://www.vcbacked.co/company/safeheal |website=VCBacked |access-date=October 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated